(Q53135049)

11 May 2018

title

FDG PET/CT predictive role in follicular lymphoma. (English)

1 reference

11 May 2018

author

Arturo Chiti

3

1 reference

11 May 2018

Pier Luigi Zinzani

6

object named as

Pier Luigi Zinzani

1 reference

11 May 2018

author name string

Egesta Lopci

1

1 reference

11 May 2018

Lucia Zanoni

2

1 reference

11 May 2018

Cristina Fonti

4

1 reference

11 May 2018

Ivan Santi

5

1 reference

11 May 2018

Stefano Fanti

7

1 reference

11 May 2018

publication date

22 February 2012

1 reference

11 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

11 May 2018

volume

39

1 reference

11 May 2018

issue

5

1 reference

11 May 2018

page(s)

864-871

1 reference

11 May 2018

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

The role of PET in monitoring therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

PET/CT in the management of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2079-Y

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22354449

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22354449

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-012-2079-Y

1 reference

11 May 2018

1 reference

11 May 2018